Xcovery Holdings, Inc.

Xcovery Holdings, Inc. company information, Employees & Contact Information

Updated May 2026

Quick answer

Xcovery Holdings, Inc. is a Pharmaceutical Manufacturing company and founded in 2006. It has approximately 17 employees on record. Contact data was last refreshed in May 2026. Find Xcovery Holdings, Inc.'s verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Xcovery Holdings, Inc. email format Xcovery Holdings, Inc. management contacts

Related company profiles:

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. Full prescribing information for Ensacove will be posted on Drugs@FDA.

Company Details

Employees
17
Founded
-
Address
168 Se 1st Street, Suite 1100, Miami,florida 33131,united States
Phone
561-835-9356
Email
in****@****ery.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
xcovery.com
Keywords
Oncology, ALK positive lung cancer, lung cancer, clinical trials, ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib, cancer research, pharma, bio-pharma, clinical studies, research, investigational agents, cancer therapy, hematology, clinical research, cancer research.
HQ
Miami, Florida
Competitors
Neurocrine Biosciences, Betta Pharmaceuticals Co., Ltd., capracare, Lumicell, Alira Health, Merus N.V., XCOVERY HOLDINGS, INC., Xcovery, ImmunityBio, Inc., Syndax Pharmaceuticals.
Looking for a particular Xcovery Holdings, Inc. employee's phone or email?

Xcovery Holdings, Inc. Questions

News

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Business Wire

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire

Xcovery’s Ensacove approved by FDA - The Pharma Letter

Xcovery’s Ensacove approved by FDA The Pharma Letter

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor - Pharmaceutical Technology

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor Pharmaceutical Technology

Xcovery Appoints Giovanni Selvaggi as CEO - citybiz

Xcovery Appoints Giovanni Selvaggi as CEO citybiz

FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC - Oncodaily

FDA has Approved Ensartinib for ALK-Positive Advanced NSCLC Oncodaily

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer - Fierce Pharma

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer Fierce Pharma

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib - Business Wire

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib Business Wire

Xcovery to Present at 8th Annual Biotech Showcase™ - PR Newswire

Xcovery to Present at 8th Annual Biotech Showcase™ PR Newswire

Xcovery hires CEO, CMO to lead assault on ALK NSCLC market - Fierce Biotech

Xcovery hires CEO, CMO to lead assault on ALK NSCLC market Fierce Biotech

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals - citybiz

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals citybiz

BRAF Mutated Non-small Cell Lung Cancer Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeut - The Globe and Mail

BRAF Mutated Non-small Cell Lung Cancer Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeut The Globe and Mail

Companies like Xcovery Holdings, Inc.

Neurocrine Biosciences logo - Similar company to Xcovery Holdings, Inc.

Neurocrine Biosciences

1.98K
Syndax Pharmaceuticals logo - Similar company to Xcovery Holdings, Inc.

Syndax Pharmaceuticals

339
Betta Pharmaceuticals Co., Ltd. logo - Similar company to Xcovery Holdings, Inc.

Betta Pharmaceutical...

22
ImmunityBio, Inc. logo - Similar company to Xcovery Holdings, Inc.

Immunitybio, Inc.

587
XCOVERY HOLDINGS, INC. logo - Similar company to Xcovery Holdings, Inc.

Xcovery Holdings, Inc.

2
Lumicell logo - Similar company to Xcovery Holdings, Inc.

Lumicell

52
Xcovery logo - Similar company to Xcovery Holdings, Inc.

Xcovery

2
capracare logo - Similar company to Xcovery Holdings, Inc.

Capracare

21
Merus N.V. logo - Similar company to Xcovery Holdings, Inc.

Merus N.V.

296
Alira Health logo - Similar company to Xcovery Holdings, Inc.

Alira Health

592

Top Xcovery Holdings, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant